$PLPL For its part, the Plandaí subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company its marijuana research will address neural disorders with. Specifically, the company believes that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, epilepsy, PTSD and post-concussion syndrome.

Plandaí expects to use its licensed Phytofare™ and Pheroid™ technologies to produce an FDA approved Phytofare™ cannabinoid complex that can address neural disorders without introducing the psychoactive element of THC to its treatments. Plandaí's extraction and hydrodynamic sheering process combined with its Pheroid™ technology, should allow it to produce an extract that captures and enhances the phytocannabinoids while omitting the psychotropic effects associated with metabolized THC.